Tiziana announces phase 2 safety trial of milciclib for treating HCC

Tiziana announced approval in Israel of a phase 2 clinical trial to test the safety of milciclib, a novel inhibitor of cell cycle dependent kinases, in patients with refractory hepatocellular carcinoma, according to a press release.

“The prognosis for liver cancer is very poor due to lack of effective therapy,” Yaron Ilan, MD, director of the department of medicine at the Hebrew University Hadassah Medical Center, Israel, and chief medical officer of Tiziana, said in the release. “We believe that milciclib holds promise as an effective anti-cancer treatment with a high safety profile.”

Previous clinical studies showed oral treatment with milciclib to be safe and well-tolerated in patients with refractory solid tumors, thymoma and thymic cancers.

Tiziana expects to enroll its first patient within the next month and report top line data by the third quarter of 2018.

Reference: www.tizianalifesciences.com